Immunologic microenvironment and personalized treatment in multiple myeloma

Bibliography

• Tassone P, Tagliaferri P, Rossi M, et al. Challenging the current approaches to multiple myeloma-related bone disease: from bisphosphonates to target therapy. Curr Cancer Drug Targets 2009;9:854-70
   Google Scholar
• Dasanu CA, Mewawalla P, Grabska J. Multiple myeloma and its therapies: to what extent do they contribute to the increased incidence of second malignant neoplasms? Curr Med Res Opin 2012;28:1129-40
   PubMed Web of Science ®Google Scholar
• Thomas A, Mailankody S, Korde N, et al. Second malignancies after multiple myeloma: from 1960s to 2010s. Blood 2012;119:2731-7
   PubMed Web of Science ®Google Scholar
• Rossi M, Young JW. Human dendritic cells: potent antigen-presenting cells at the crossroads of innate and adaptive immunity. J Immunol 2005;175:1373-81
   PubMed Web of Science ®Google Scholar
• Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009;9:162-74
   PubMed Web of Science ®Google Scholar
• Gatti E, Pierre P. Understanding the cell biology of antigen presentation: the dendritic cell contribution. Curr Opin Cell Biol 2003;15:468-73
   PubMed Web of Science ®Google Scholar
• Amodio G, Gregori S. Dendritic cells a double-edge sword in autoimmune responses. Front Immunol 2012;3:233
   PubMed Web of Science ®Google Scholar
• Gregori S, Tomasoni D, Pacciani V, et al. Differentiation of type 1 T regulatory cells (Tr1) by tolerogenic DC-10 requires the IL-10-dependent ILT4/HLA-G pathway. Blood 2010;116:935-44
   PubMed Web of Science ®Google Scholar
• Ratta M, Fagnoni F, Curti A, et al. Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. Blood 2002;100:230-7
   PubMed Web of Science ®Google Scholar
• Yang DH, Park JS, Jin CJ, et al. The dysfunction and abnormal signaling pathway of dendritic cells loaded by tumor antigen can be overcome by neutralizing VEGF in multiple myeloma. Leuk Res 2009;33:665-70
   PubMed Web of Science ®Google Scholar
• Brown R, Murray A, Pope B, et al. Either interleukin-12 or interferon-gamma can correct the dendritic cell defect induced by transforming growth factor beta in patients with myeloma. Br J Haematol 2004;125:743-8
   PubMed Web of Science ®Google Scholar
• Dhodapkar KM, Krasovsky J, Williamson B, et al. Antitumor monoclonal antibodies enhance cross-presentation ofcCellular antigens and the generation of myeloma-specific killer T cells by dendritic cells. J Exp Med 2002;195:125-33
   PubMed Web of Science ®Google Scholar
• Correale P, Botta C, Cusi MG, et al. Cetuximab +/- chemotherapy enhances dendritic cell-mediated phagocytosis of colon cancer cells and ignites a highly efficient colon cancer antigen-specific cytotoxic T-cell response in vitro. Int J Cancer 2012;130:1577-89
   PubMed Web of Science ®Google Scholar
• Botta C, Bestoso E, Apollinari S, et al. Immune-modulating effects of the newest cetuximab-based chemoimmunotherapy regimen in advanced colorectal cancer patients. J Immunother 2012;35:440-7
   Google Scholar
• Nguyen-Pham TN, Lee YK, Kim HJ, et al. Immunotherapy using dendritic cells against multiple myeloma: how to improve? Clin Dev Immunol 2012;2012:397648
   PubMedGoogle Scholar
• Sharma A, Khan R, Joshi S, et al. Dysregulation in T helper 1/T helper 2 cytokine ratios in patients with multiple myeloma. Leuk Lymphoma 2010;51:920-7
   PubMed Web of Science ®Google Scholar
• Maecker B, Anderson KS, von Bergwelt-Baildon MS, et al. Viral antigen-specific CD8+ T-cell responses are impaired in multiple myeloma. Br J Haematol 2003;121:842-8
   PubMed Web of Science ®Google Scholar
• Gorgun G, Calabrese E, Soydan E, et al. Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma. Blood 2010;116:3227-37
   PubMed Web of Science ®Google Scholar
• Fujimoto M, Tsutsui H, Yumikura-Futatsugi S, et al. A regulatory role for suppressor of cytokine signaling-1 in T(h) polarization in vivo. Int Immunol 2002;14:1343-50
   PubMed Web of Science ®Google Scholar
• Kimura A, Naka T, Muta T, et al. Suppressor of cytokine signaling-1 selectively inhibits LPS-induced IL-6 production by regulating JAK-STAT. Proc Natl Acad Sci USA 2005;102:17089-94
   PubMed Web of Science ®Google Scholar
• Sakaguchi S. Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 2005;6:345-52
   PubMed Web of Science ®Google Scholar
• Joshua DE, Brown RD, Ho PJ, et al. Regulatory T cells and multiple myeloma. Clin Lymphoma Myeloma 2008;8:283-6
   PubMedGoogle Scholar
• Chung DJ, Rossi M, Romano E, et al. Indoleamine 2,3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells. Blood 2009;114:555-63
   PubMed Web of Science ®Google Scholar
• Munn DH, Mellor AL, Rossi M, et al. Dendritic cells have the option to express IDO-mediated suppression or not. Blood 2005;105:2618
   PubMed Web of Science ®Google Scholar
• Mahnke K, Ring S, Johnson TS, et al. Induction of immunosuppressive functions of dendritic cells in vivo by CD4+CD25+ regulatory T cells: role of B7-H3 expression and antigen presentation. Eur J Immunol 2007;37:2117-26
   PubMed Web of Science ®Google Scholar
• Allan SE, Passerini L, Bacchetta R, et al. The role of 2 FOXP3 isoforms in the generation of human CD4+ Tregs. J Clin Invest 2005;115:3276-84
   PubMed Web of Science ®Google Scholar
• Wing K, Onishi Y, Prieto-Martin P, et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science 2008;322:271-5
   PubMed Web of Science ®Google Scholar
• Strauss L, Bergmann C, Szczepanski MJ, et al. Expression of ICOS on human melanoma-infiltrating CD4+CD25highFoxp3+ T regulatory cells: implications and impact on tumor-mediated immune suppression. J Immunol 2008;180:2967-80
   PubMed Web of Science ®Google Scholar
• Yamaguchi T, Wing JB, Sakaguchi S. Two modes of immune suppression by Foxp3(+) regulatory T cells under inflammatory or non-inflammatory conditions. Semin Immunol 2011;23:424-30
   PubMed Web of Science ®Google Scholar
• Correale P, Rotundo MS, Del Vecchio MT, et al. Regulatory (FoxP3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy. J Immunother 2010;33:435-41
   PubMed Web of Science ®Google Scholar
• Correale P, Rotundo MS, Botta C, et al. Tumor infiltration by chemokine receptor 7 (CCR7)(+) T-lymphocytes is a favorable prognostic factor in metastatic colorectal cancer. Oncoimmunology 2012;1:531-2
   PubMed Web of Science ®Google Scholar
• Correale P, Rotundo MS, Botta C, et al. Tumor infiltration by T lymphocytes expressing chemokine receptor 7 (CCR7) is predictive of favorable outcome in patients with advanced colorectal carcinoma. Clin Cancer Res 2012;18:850-7
   PubMed Web of Science ®Google Scholar
• Prabhala RH, Neri P, Bae JE, et al. Dysfunctional T regulatory cells in multiple myeloma. Blood 2006;107:301-4
   PubMed Web of Science ®Google Scholar
• Song W, van der Vliet HJ, Tai YT, et al. Generation of antitumor invariant natural killer T cell lines in multiple myeloma and promotion of their functions via lenalidomide: a strategy for immunotherapy. Clin Cancer Res 2008;14:6955-62
   PubMed Web of Science ®Google Scholar
• Beyer M, Kochanek M, Giese T, et al. In vivo peripheral expansion of naive CD4+CD25high FoxP3+ regulatory T cells in patients with multiple myeloma. Blood 2006;107:3940-9
   PubMed Web of Science ®Google Scholar
• Muthu Raja KR, Rihova L, Zahradova L, et al. Increased T regulatory cells are associated with adverse clinical features and predict progression in multiple myeloma. PloS One 2012;7:e47077
   PubMed Web of Science ®Google Scholar
• Dhodapkar KM, Barbuto S, Matthews P, et al. Dendritic cells mediate the induction of polyfunctional human IL17-producing cells (Th17-1 cells) enriched in the bone marrow of patients with myeloma. Blood 2008;112:2878-85
   PubMed Web of Science ®Google Scholar
• Prabhala RH, Pelluru D, Fulciniti M, et al. Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma. Blood 2010;115:5385-92
   PubMed Web of Science ®Google Scholar
• Noonan K, Marchionni L, Anderson J, et al. A novel role of IL-17-producing lymphocytes in mediating lytic bone disease in multiple myeloma. Blood 2010;116:3554-63
   PubMed Web of Science ®Google Scholar
• Kotake S, Udagawa N, Takahashi N, et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 1999;103:1345-52
   PubMed Web of Science ®Google Scholar
• Kotsakis A, Harasymczuk M, Schilling B, et al. Myeloid-derived suppressor cell measurements in fresh and cryopreserved blood samples. J Immunol Methods 2012;381:14-22
   PubMed Web of Science ®Google Scholar
• Serafini P, Carbley R, Noonan KA, et al. High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res 2004;64:6337-43
   PubMed Web of Science ®Google Scholar
• Bunt SK, Yang L, Sinha P, et al. Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res 2007;67:10019-26
   PubMed Web of Science ®Google Scholar
• Hoechst B, Gamrekelashvili J, Manns MP, et al. Plasticity of human Th17 cells and iTregs is orchestrated by different subsets of myeloid cells. Blood 2011;117:6532-41
   PubMed Web of Science ®Google Scholar
• Görgün GT, Whitehill G, Anderson JL, et al. Tumor promoting immune suppressive myeloid derived suppressor cells in multiple myeloma microenvironment. Blood 2013;121:2975-87
   PubMed Web of Science ®Google Scholar
• Pessoa de Magalhaes RJ, Vidriales MB, Paiva B, et al. Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry. Haematologica 2013;98:79-86
   PubMed Web of Science ®Google Scholar
• Paiva B, Perez-Andres M, Vidriales MB, et al. Competition between clonal plasma cells and normal cells for potentially overlapping bone marrow niches is associated with a progressively altered cellular distribution in MGUS vs myeloma. Leukemia 2011;25:697-706
   PubMed Web of Science ®Google Scholar
• Lanier LL. NK cell recognition. Annu Rev Immunol 2005;23:225-74
   PubMed Web of Science ®Google Scholar
• Carbone E, Neri P, Mesuraca M, et al. HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells. Blood 2005;105:251-8
   PubMed Web of Science ®Google Scholar
• Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002;295:2097-100
   PubMed Web of Science ®Google Scholar
• Dhodapkar MV, Geller MD, Chang DH, et al. A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma. J Exp Med 2003;197:1667-76
   PubMed Web of Science ®Google Scholar
• Dhodapkar MV, Richter J. Harnessing natural killer T (NKT) cells in human myeloma: progress and challenges. Clin Immunol 2011;140:160-6
   PubMed Web of Science ®Google Scholar
• Chang DH, Deng H, Matthews P, et al. Inflammation-associated lysophospholipids as ligands for CD1d-restricted T cells in human cancer. Blood 2008;112:1308-16
   PubMed Web of Science ®Google Scholar
• Salio M, Cerundolo V. Linking inflammation to natural killer T cell activation. PLoS Biol 2009;7:e1000226
   PubMedGoogle Scholar
• Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer 2004;4:349-60
   PubMed Web of Science ®Google Scholar
• Hideshima T, Chauhan D, Hayashi T, et al. Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma. Oncogene 2003;22:8386-93
   PubMed Web of Science ®Google Scholar
• Mitsiades N, Mitsiades CS, Poulaki V, et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci USA 2002;99:14374-9
   PubMed Web of Science ®Google Scholar
• Chang CL, Hsu YT, Wu CC, et al. Immune mechanism of the antitumor effects generated by bortezomib. J Immunol 2012;189:3209-20
   PubMed Web of Science ®Google Scholar
• Spisek R, Charalambous A, Mazumder A, et al. Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications. Blood 2007;109:4839-45
   PubMed Web of Science ®Google Scholar
• Schumacher LY, Vo DD, Garban HJ, et al. Immunosensitization of tumor cells to dendritic cell-activated immune responses with the proteasome inhibitor bortezomib (PS-341, Velcade). J Immunol 2006;176:4757-65
   PubMed Web of Science ®Google Scholar
• Naujokat C, Berges C, Hoh A, et al. Proteasomal chymotrypsin-like peptidase activity is required for essential functions of human monocyte-derived dendritic cells. Immunology 2007;120:120-32
   PubMed Web of Science ®Google Scholar
• Berges C, Haberstock H, Fuchs D, et al. Proteasome inhibition activates the mitochondrial pathway of apoptosis in human CD4+ T cells. J Cell Biochem 2009;108:935-46
   PubMed Web of Science ®Google Scholar
• Corral LG, Haslett PA, Muller GW, et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 1999;163:380-6
   PubMed Web of Science ®Google Scholar
• Schafer PH, Gandhi AK, Loveland MA, et al. Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs. J Pharmacol Exp Ther 2003;305:1222-32
   PubMed Web of Science ®Google Scholar
• Haslett PA, Hanekom WA, Muller G, et al. Thalidomide and a thalidomide analogue drug costimulate virus-specific CD8+ T cells in vitro. J Infect Dis 2003;187:946-55
   PubMed Web of Science ®Google Scholar
• Chang DH, Liu N, Klimek V, et al. Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood 2006;108:618-21
   PubMed Web of Science ®Google Scholar
• Hayashi T, Hideshima T, Akiyama M, et al. Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application. Br J Haematol 2005;128:192-203
   PubMed Web of Science ®Google Scholar
• Lynch RG, Graff RJ, Sirisinha S, et al. Myeloma proteins as tumor-specific transplantation antigens. Proc Natl Acad Sci USA 1972;69:1540-4
   PubMed Web of Science ®Google Scholar
• Li Y, Bendandi M, Deng Y, et al. Tumor-specific recognition of human myeloma cells by idiotype-induced CD8(+) T cells. Blood 2000;96:2828-33
   PubMed Web of Science ®Google Scholar
• Rasmussen T, Hansson L, Osterborg A, et al. Idiotype vaccination in multiple myeloma induced a reduction of circulating clonal tumor B cells. Blood 2003;101:4607-10
   PubMed Web of Science ®Google Scholar
• Massaia M, Borrione P, Battaglio S, et al. Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy. Blood 1999;94:673-83
   PubMed Web of Science ®Google Scholar
• Titzer S, Christensen O, Manzke O, et al. Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects. Br J Haematol 2000;108:805-16
   PubMed Web of Science ®Google Scholar
• Romano E, Rossi M, Ratzinger G, et al. Peptide-loaded Langerhans cells, despite increased IL15 secretion and T-cell activation in vitro, elicit antitumor T-cell responses comparable to peptide-loaded monocyte-derived dendritic cells in vivo. Clin Cancer Res 2011;17:1984-97
   PubMed Web of Science ®Google Scholar
• Gong J, Koido S, Chen D, et al. Immunization against murine multiple myeloma with fusions of dendritic and plasmacytoma cells is potentiated by interleukin 12. Blood 2002;99:2512-17
   PubMed Web of Science ®Google Scholar
• Luptakova K, Rosenblatt J, Glotzbecker B, et al. Lenalidomide enhances anti-myeloma cellular immunity. Cancer Immunol Immunother 2013;62:39-49
   PubMed Web of Science ®Google Scholar
• Gober HJ, Kistowska M, Angman L, et al. Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells. J Exp Med 2003;197:163-8
   PubMed Web of Science ®Google Scholar
• Castella B, Riganti C, Fiore F, et al. Immune modulation by zoledronic acid in human myeloma: an advantageous cross-talk between Vgamma9Vdelta2 T cells, alphabeta CD8+ T cells, regulatory T cells, and dendritic cells. J Immunol 2011;187:1578-90
   PubMed Web of Science ®Google Scholar
• Tai YT, Dillon M, Song W, et al. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood 2008;112:1329-37
   PubMed Web of Science ®Google Scholar
• van Rhee F, Szmania SM, Dillon M, et al. Combinatorial efficacy of anti-CS1 monoclonal antibody elotuzumab (HuLuc63) and bortezomib against multiple myeloma. Mol Cancer Ther 2009;8:2616-24
   PubMed Web of Science ®Google Scholar
• Lonial S, Vij R, Harousseau JL, et al. Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma. J Clin Oncol 2012;30:1953-9
   PubMed Web of Science ®Google Scholar
• Carter L, Fouser LA, Jussif J, et al. PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2. Eur J Immunol 2002;32:634-43
   PubMed Web of Science ®Google Scholar
• Rosenblatt J, Glotzbecker B, Mills H, et al. PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine. J Immunother 2011;34:409-18
   PubMed Web of Science ®Google Scholar
• Benson DM Jr, Bakan CE, Mishra A, et al. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood 2010;116:2286-94
   PubMed Web of Science ®Google Scholar
• van der Veer MS, de Weers M, van Kessel B, et al. The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapies. Blood Cancer J 2011;1:e41
   PubMed Web of Science ®Google Scholar
• Plesner T, Lokhorst H, Gimsing P, et al. Daratumumab, a CD38 monoclonal antibody in patients with multiple myeloma - data from a dose-escalation phase I/II study. ASH Annu Meet Abstr 2012;120:73
   Google Scholar
• White D, Kassim A, Bhaskar B, et al. Results from AMBER, a randomized phase 2 study of bevacizumab and bortezomib versus bortezomib in relapsed or refractory multiple myeloma. Cancer 2013;119:339-47
   PubMed Web of Science ®Google Scholar
• Tassone P, Galea E, Forciniti S, et al. The IL-6 receptor super-antagonist Sant7 enhances antiproliferative and apoptotic effects induced by dexamethasone and zoledronic acid on multiple myeloma cells. Int J Oncol 2002;21:867-73
   PubMed Web of Science ®Google Scholar
• Danylesko I, Beider K, Shimoni A, et al. Novel strategies for immunotherapy in multiple myeloma: previous experience and future directions. Clin Dev Immunol 2012;2012:753407
   PubMedGoogle Scholar
• Tassone P, Tagliaferri P. Editorial: new approaches in the treatment of multiple myeloma: from target-based agents to the new era of microRNAs (dedicated to the memory of Prof. Salvatore Venuta). Curr Cancer Drug Targets 2012;12:741-2
   PubMed Web of Science ®Google Scholar
• Tagliaferri P, Rossi M, Di Martino MT, et al. Promises and challenges of microRNA-based treatment of multiple myeloma. Curr Cancer Drug Targets 2012;12:838-46
   PubMed Web of Science ®Google Scholar
• Rossi M, Pitari MR, Amodio N, et al. miR-29b negatively regulates human osteoclastic cell differentiation and function: implications for the treatment of multiple myeloma-related bone disease. J Cell Physiol 2012; [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Di Martino MT, Leone E, Amodio N, et al. Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence. Clin Cancer Res 2012;18:6260-70
   PubMed Web of Science ®Google Scholar
• Amodio N, Leotta M, Bellizzi D, et al. DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma. Oncotarget 2012;3:1246-58
   PubMed Web of Science ®Google Scholar
• Amodio N, Di Martino MT, Foresta U, et al. miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1. Cell Death Disease 2012;3:e436
   PubMed Web of Science ®Google Scholar
• Leone E, Morelli E, Di Martino MT, et al. Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth. Clin Cancer Res 2013;19(8):2096-106
   PubMed Web of Science ®Google Scholar
• Di Martino MT, Gulla A, Cantafio ME, et al. In vitro and in vivo anti-tumor activity of miR-221/222 inhibitors in multiple myeloma. Oncotarget 2013;4:242-55
   PubMed Web of Science ®Google Scholar
• Tassone P, Neri P, Carrasco DR, et al. A clinically relevant SCID-hu in vivo model of human multiple myeloma. Blood 2005;106:713-16
   Google Scholar
• Tassone P, Neri P, Burger R, et al. Mouse models as a translational platform for the development of new therapeutic agents in multiple myeloma. Curr Cancer Drug Targets 2012;12:814-22
   PubMed Web of Science ®Google Scholar
• Calimeri T, Battista E, Conforti F, et al. A unique three-dimensional SCID-polymeric scaffold (SCID-synth-hu) model for in vivo expansion of human primary multiple myeloma cells. Leukemia 2011;25:707-11
   PubMed Web of Science ®Google Scholar
• Neri P, Tagliaferri P, Di Martino MT, et al. In vivo anti-myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor. Br J Haematol 2008;143:520-31
   PubMed Web of Science ®Google Scholar